Search results
Showing 61 to 75 of 1371 results for patients and public
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)
This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
In development [GID-TA11423] Expected publication date: 11 December 2024
In development [GID-TA11348] Expected publication date: TBC
In development [GID-TA11514] Expected publication date: 25 September 2024
In development [GID-TA11512] Expected publication date: TBC
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Introduction
- List of quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
Coexisting severe mental illness and substance misuse (QS188)
This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.
In development [GID-TA11351] Expected publication date: TBC
In development [GID-TA11364] Expected publication date: TBC
In development [GID-TA11352] Expected publication date: 26 February 2025
In development [GID-TA11471] Expected publication date: 03 July 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]
In development [GID-TA11062] Expected publication date: 30 October 2024
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]
In development [GID-TA11148] Expected publication date: 14 August 2024
Somapacitan for treating growth hormone deficiency in children [ID6178]
In development [GID-TA11153] Expected publication date: TBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274
In development [GID-TA11280] Expected publication date: 18 September 2024